Weill Medical College of Cornell University

• Home
• Cancer and Blood Disorders
  • Solid Tumor
    • Bladder Cancer
    • Breast Cancer
    • Colon Cancer
    • Esophageal Cancer
    • Gastric/Stomach Cancer
    • Head and Neck Cancer
    • Kidney/Renal Cancer
    • Liver Cancer
    • Lung Cancer
    • Melanoma
    • Ovarian/Peritoneal/Fallopian Tube Cancer
    • Pancreatic Cancer
    • Prostate Cancer
    • Sarcoma
    • Soft Tissue Cancer

  • Multiple Myeloma
  • Leukemia and Myeloproliferative Disorders
    • Acute Lymphocytic Leukemia
    • Acute Myeloid Leukemia
    • Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
    • Chronic Myeloid Leukemia
    • Myelodysplastic Syndrome
    • Myelofibrosis
    • Polycythemia Vera

  • Lymphoma
    • Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
    • Hodgkin’s Lymphoma
    • Non-Hodgkin’s Lymphoma
    • Waldenstrom’s Macroglobulinemia

  • Bone Marrow Transplant (BMT)
  • Benign Hematology
    • Anticoagulation
    • Bleeding and Platelet Disorders
• Cardiovascular/Heart
  • Aortic Aneurysms
  • Arrhythmias
  • Atrial Fibrillations
  • Coronary Artery Disease (CAD)
  • Hypertension/High Blood Pressure
  • Inherited Heart Disease
  • Myocardial Infarction
  • Other Cardiovascular Diseases and Conditions
• Diabetes
• Gastrointestinal Diseases
  • Hepatitis
    • Hepatitis B
    • Hepatitis C
    • Hepatitis/HIV Co-Infection
  • Cancers of the Colon, Pancreas, Esophagus, Stomach
  • Celiac Disease
  • Crohn's Disease
  • Inflammatory Bowel Disease
  • Ulcerative Colitis
  • Other Gastrointestinal Diseases
• Geriatrics
  • Pain and Palliative Care
• Hepatitis
  • Hepatitis B
  • Hepatitis C
  • Hepatitis/HIV Co-infection
• HIV/AIDS and Infectious Diseases
• Kidney/Renal Disease
  • Kidney Transplants
• Lifestyle/Behavior Change
  • Medication Adherence
  • Hypertension Control
  • Colon Cancer Screening/Risk Reduction
• Pulmonary (Lung/Respiratory Tract) Disease
  • Asthma
  • Pneumonia
  • Pulmonary Fibrosis
  • Smokers
  • Other Respiratory/Lung Conditions
• Rheumatology Autoimmune Disease and Orthopedic Surgery
 
• Sleep Disorders
• Weight Loss/Obesity
• Healthy Volunteers

CALGB 50303: Phase III Randomized Study of R-CHOP vs. Dose-Adjusted EPOCH-R with Molecular Profiling in Untreated De Novo Diffuse Large B-cell Lymphomas

Study Status

Open to Enrollment

Study Description

Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving rituximab together with combination chemotherapy may kill more cancer cells. It is not yet known which combination chemotherapy regimen is more effective when given with rituximab in treating diffuse large B-cell non-Hodgkin's lymphoma.

This phase III trial is studying rituximab when given together with two different combination chemotherapy regimens to compare how well they work in treating patients with diffuse large B-cell non-Hodgkin's lymphoma.             

Patients will be randomized to one of two treatment arms:

• Arm A: Patients will receive R-CHOP Chemotherapy
• Arm B: Patients will receive dose-adjusted EPOCH-R Chemotherapy

Click here to visit our lymphoma blog.

Disease Status and/or Stage

Untreated De Novo Diffuse Large B-Cell Lymphoma with Stage II, III or IV Disease

Sponsor

Cancer and Leukemia Group B; National Cancer Institute

Key Eligibility

• Men and women age 18 and older
  
• Untreated patients with histologically confirmed de novo B-cell non-Hodgkin's lymphoma (NHL)
  
• Stage II, III or IV disease
  
• More detailed eligibility criteria discussed when you contact the study team

Principal Investigator

John Leonard, MD

Contact

• June Greenberg, RN
• (212) 746-2651
• [email protected]